drugset
drugset / Trial / NCT03737851

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

NCT03737851 ↗

Phase 2 Completed 208 enrolled AbbVie
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of elezanumab in participants with relapsing Multiple Sclerosis (RMS).

Timeline

Start
2018-12-11
Primary completion
2021-08-09
Completion
2021-09-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Elezanumab Monoclonal antibody — Intravenous

Indications

multiple sclerosis